Lenalidomide Biocon (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This binding changes the complex’s substrate specificity, leading to ubiquitination and proteasomal degradation of the transcription factors Ikaros and Aiolos. The loss of these factors disrupts malignant cell survival, reduces angiogenesis, and enhances immune‑mediated tumor killing.

The exact dose and schedule of Lenalidomide Biocon are set by the prescribing clinician based on the specific indication, disease stage, patient weight, renal function, and any concomitant therapies. Because dosing can vary widely, patients should follow the individualized prescription provided by their oncologist or hematologist.

Lenalidomide is classified as pregnancy category X because it is teratogenic and can cause severe fetal harm. It is contraindicated in pregnancy, and effective contraception is required for both men and women of reproductive potential. The drug is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant.

To request Lenalidomide Biocon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required cold‑chain handling) and the necessary import documentation.

Lenalidomide is a second‑generation immunomodulatory drug (IMiD) that offers greater potency and a more favorable safety profile than thalidomide, while retaining similar mechanisms of action. Compared with pomalidomide, another newer IMiD, lenalidomide is often used earlier in treatment algorithms and has a broader label for myelodysplastic syndromes with del(5q).

Lenalidomide Biocon tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original blister pack or container, protect it from moisture and direct light, and avoid storing it in areas with high humidity or temperature fluctuations.

The medication is taken orally as a whole tablet, usually with or without food as directed by the prescriber. Patients should swallow the tablet whole with water and avoid crushing or chewing it, unless the prescribing physician provides specific instructions to do so.

The most critical safety concerns include the risk of severe neutropenia or thrombocytopenia, which can lead to infections or bleeding, and the potential for thromboembolic events such as deep‑vein thrombosis or pulmonary embolism. Additionally, lenalidomide carries a teratogenic risk, so strict contraception is mandatory for patients of reproductive age.

Lenalidomide Biocon should not be used by individuals who are pregnant, planning to become pregnant, or breastfeeding. It is also contraindicated in patients with known hypersensitivity to lenalidomide or any of its excipients, and caution is advised for those with severe renal impairment or uncontrolled infections.